Table 4.
Significant bivariate associations between exposure variables and rate of plaque growth
| Variable | β coefficient (95% CI) | P |
|---|---|---|
| Creatinine clearance quintile | 0.02 | |
| Q1 (<23 ml/min/1.73 m2) | −0.22 (−0.34 to −0.10) | 0.0001 |
| Q2 (23 to 29 ml/min/1.73 m2) | −0.10 (−0.22 to 0.02) | 0.1 |
| Q3 (29 to 35 ml/min/1.73 m2) | −0.10 (−0.22 to 0.02) | 0.1 |
| Q4 (35 to 43 ml/min/1.73 m2) | −0.07 (−0.19 to 0.05) | 0.2 |
| Q5 (>43 ml/min/1.73 m2) (reference) | 0.0 (reference) | |
| Age (per decade) | −0.07 (−0.11 to −0.03) | 0.001 |
| Female gender | −0.10 (−0.18 to −0.02) | 0.02 |
| Pulse pressure (per 10 mmHg) | −0.02 (−0.04 to −0.001) | 0.03 |
| PTH (natural log pmol/L) | −0.03 (−0.06 to −0.02) | 0.03 |
| Medications | ||
| HMG-CoA reductase inhibitors | 0.08 (−0.003 to 0.17) | 0.06 |
| calcium-based phosphate binders | 0.12 (0.02 to 0.21) | 0.02 |
| Baseline plaque area ( per mm2/3) | −0.07 (−0.09 to −0.05) | <0.0001 |
| Center | <0.0001 | |
| 1 (reference) | 0.0 | |
| 2 | 0.02 (−0.16 to 0.19) | 0.9 |
| 3 | −0.07 (−0.16 to 0.02) | 0.1 |
| 4 | −0.01 (−0.21 to 0.19) | 0.9 |
| 5 | 0.20 (0.11 to 0.3) | <0.0001 |
The following variables were not significant on bivariate testing and are not shown: Diabetes, smoking, history of cardiovascular disease, systolic and diastolic BP, albumin, proteinuria, hemoglobin, calcium, phosphate, lipids (Total, LDL, and HDL cholesterol, triglycerides), Medication use (ACEi or ARB, diuretic, calcium channel blockers, beta blockers, HMG-CoA reductase inhibitors, fibrates, vitamin D, ASA, erythropoietin; number of plaque measurements, duration of follow-up